HHS unveiled Wednesday (March 15) the first list of Part B drugs for which drug makers will have to pay inflation rebates . Beginning April 1, Medicare beneficiaries will have their coinsurance lowered for 27 Part B drugs for which prices rose faster than the rate of inflation during the last quarter of 2022, and out-of-pocket expenses could decrease by as low as $2 to up to $390 per average dose. HHS Secretary Xavier Becerra told reporters that Medicare’s new...